



Practitioner's Docket No. MPI04-002OMNIM

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:	Maria A. Glucksmann, et al.		
Application No.:	10/782,695	Group No.:	1646
Filed:	February 19, 2004	Examiner:	Jiang, Dong
For:	NOVEL 14275, 54420, 8797, 27439, 68730, 69112 AND 52908 MOLECULES AND USES THEREFOR		

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT

**IDENTIFICATION OF TIME OF FILING THE ACCOMPANYING
INFORMATION DISCLOSURE STATEMENT**

1. The information disclosure statement submitted herewith is being filed:

Within three months of the filing date of the application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 C.F.R. section 1.97(b).

OR

After three months of the filing date of this national application or the date of entry of the national stage as set forth in Section 1.491 in an international application or after the mailing date of the first Office action on the merits, whichever event occurred last but *before* the mailing date of either:

- (1) a final action under Section 1.113,
- (2) a notice of allowance under Section 1.311, or
- (3) an action that otherwise closes prosecution in the application

CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10*

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

deposited with the United States Postal Service in an envelope addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.
37 C.F.R. SECTION 1.8(a)

37 C.F.R. SECTION 1.10*

with sufficient postage as first class mail. as "Express Mail Post Office to Addressee" Mailing Label No.

TRANSMISSION

transmitted by facsimile to the Patent and Trademark Office.



Signature
Sean Hunziker

(type or print name of person certifying)

***WARNING:** Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

Practitioner's Docket No. MPI04-002OMNIM

whichever occurs first.

Accompanying this transmittal is the fee set forth in 37 C.F.R. Section 1.17(p) for submission of an information disclosure statement under Section 1.97(c). (\$180.00).

Each item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. 37 C.F.R. Section 1.97(e)(1).

No item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application and to the knowledge of the person signing the statement after making reasonable inquiry, was known to any individual designated in Section 1.56(c) more than three months prior to the filing of the information disclosure statement. 37 C.F.R. Section 1.97(e)(2).

FEE PAYMENT

2. The fee due is set forth in 37 C.F.R. Section 1.17(p) for submission of an information disclosure statement under Section 1.97(c) (\$180.00).

Applicant believes no fee is due in connection with this submission.

Fee due \$0.00

METHOD OF PAYMENT OF FEE

3. Attached is a check in the amount of \$ _____.
 Charge Account No. 501668 in the amount of \$0.00.
 A duplicate of this request is attached.

If any additional fees are due, please charge Account 501668.

July 20, 2006

MILLENNIUM PHARMACEUTICALS, INC.

By *Mario Cloutier*
Mario Cloutier
Registration No. 57, 225
40 Lansdowne Street
Cambridge, MA 02139
Telephone – (617) 577-3522
Facsimile – (617) 551-8820



Practitioner's Docket No. MPI04-002OMNIM

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:	Maria A. Glucksman, et al.		
Application No.:	10/782,695	Group No.:	1646
Filed:	February 19, 2004	Examiner:	Jiang, Dong
For:	NOVEL 14275, 54420, 8797, 27439, 68730, 69112 AND 52908 MOLECULES AND USES THEREFOR		

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

List of Sections Forming Part of This Information Disclosure Statement

The following sections are being submitted for this Information Disclosure Statement:

1. Preliminary Statements;
2. Form PTO/SB/08A and Form PTO/SB/08B (substitute for Form PTO-1449) (5 pages);
3. Copy of Form PTO-892 – Part of Paper No. 12 as cited in parent application Serial No. 09/945,254 (1 page);
5. Identification of Prior Application in Which Listed Information Was Already Cited and for Which No Copies Are Submitted or Need Be Submitted (Citation Nos. N, U as Cited in Form PTO-892, Citation Nos. A1, A2-A16, B1-B9, B15-B17, C1-C5 as Cited in Forms PTO/SB/08A and PTO/SB/08B);
6. Identification of Person(s) Making This Information Disclosure Statement

CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10*

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

deposited with the United States Postal Service in an envelope addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

37 C.F.R. SECTION 1.8(a)

with sufficient postage as first class mail.

37 C.F.R. SECTION 1.10*

as "Express Mail Post Office to Addressee" Mailing Label No.

TRANSMISSION

transmitted by facsimile to the Patent and Trademark Office.

Signature


Sean Hunziker
(type or print name of person certifying)

Date: July 20, 2006

***WARNING:** Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

Practitioner's Docket No. MPI04-002OMNIM

Preliminary statements

Applicants submit herewith patents, publications or other information, of which they are aware that they believe may be material to the examination of this application, and in respect of which, there may be a duty to disclose.

The filing of this information disclosure statement shall not be construed as a representation that a search has been made (37 C.F.R. section 1.97(g)), an admission that the information cited is, or is considered to be, material to patentability, or that no other material information exists.

The filing of this information disclosure statement shall not be construed as an admission against interest in any manner. Notice of January 9, 1992, 1135 O.G. 13-25, at 25.

**Identification of Prior Application in Which Listed Information Was Already Cited
and for Which No Copies Are Submitted or Need Be Submitted**

This application relies, under 35 U.S.C. section 120, on the earlier filing date of prior application Serial No. 09/945,254, filed on August 31, 2001.


The cited references (N, U) in Form PTO-892 – Part of Paper No. 12, and (A1, A2-A16, B1-B9, B15-B17, C1-C5) in forms PTO/SB/08A and PTO/SB/08B were submitted to, and/or cited by, the Office in the prior application(s) and, therefore, are not required to be provided in this application. However, the undersigned will provide additional copies upon request.

July 20, 2006

MILLENNIUM PHARMACEUTICALS, INC.

By: Mario Cloutier

Mario Cloutier
Registration No. 57, 225
40 Lansdowne Street
Cambridge, MA 02139
Telephone – (617) 577-3522
Facsimile – (617) 551-8820



JUL 24 2001

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 1

Sheet 1 of 1 Attorney Docket Number: MA 104-00200M-NM

Complete if Known

Application Number	10/782,695
Filing Date	February 19, 2004
First Named Inventor	Maria A. Glucksmann, et al.
Group Art Unit	1646
Examiner Name	Jiang, Dong
Attorney Docket Number	MPI04-002OMNIM

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document (MM-DD-YYYY)	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
	A1	WO 01/07611	A2	GENENTECH, INC.	02-01-2001	Entire document

FOREIGN PATENT DOCUMENTS

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation design number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁸Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, P.O. Box 1450, Alexandria, VA 22313-1450.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<p>Substitute for form 1449B/PTO JUL 24 2006 INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)</p>				Complete if Known	
Sheet	1	of	3	Application Number	10/782,695
				Filing Date	February 19, 2004
				First Named Inventor	Maria A. Glucksmann, et al.
				Group Art Unit	1646
				Examiner Name	Jiang, Dong
				Attorney Docket Number	MPI04-002OMNIM

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No. ¹	Include the name of the author (in CAPTIAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and-or country where published.				T ²
	A2	GU, J., et al., "BM Homo Sapiens cDNA Clone BMFAUC07 5', mRNA Sequence," Created October 19, 2000, (sequence) GenBank [online] Bethesda, MD, USA: National Center for Biotechnology Information [retrieved on October 5, 2001]. Retrieved from the Internet: URL: http://www.ncbi.nlm.nih.gov/ . GenBank Accession No. AV758454.				
	A3	XU, X., et al., "DCB Homo Sapiens cDNA Clone DCBALF01 5', mRNA Sequence," Created October 11, 2000, (sequence) GenBank [online] Bethesda, MD, USA: National Center for Biotechnology Information [retrieved on October 5, 2001]. Retrieved from the Internet: URL: http://www.ncbi.nlm.nih.gov/ . GenBank Accession No. AV714678.				
	A4	STRAUSBERG, ROBERT, "NIH_MGC_89 Homo Sapiens cDNA Clone IMAGE: 4414526 5' mRNA Sequence," Created February 12, 2001, (sequence) GenBank [online] Bethesda, MD, USA: National Center for Biotechnology Information [retrieved on October 5, 2001]. Retrieved from the Internet: URL: http://www.ncbi.nlm.nih.gov/ . GenBank Accession No. BG249800.				
	A5	XU, X., et al., "DCB Homo Sapiens cDNA Clone DCBAWH06 5', mRNA Sequence," Created October 11, 2000, (sequence) GenBank [online] Bethesda, MD, USA: National Center for Biotechnology Information [retrieved on October 5, 2001]. Retrieved from the Internet: URL: http://www.ncbi.nlm.nih.gov/ . GenBank Accession No. AV714776.				
	A6	DIAS NETO, E., et al., "RC2-CT0320-060200-017-e11 CT0320 Homo Sapiens cDNA, mRNA Sequence," Created May 19, 2000, (sequence) GenBank [online] Bethesda, MD, USA: National Center for Biotechnology Information [retrieved on October 5, 2001]. Retrieved from the Internet: URL: http://www.ncbi.nlm.nih.gov/ . GenBank Accession No. AW857691.				
	A7	STRAUSBERG, ROBERT, "602667860F1 NIH_MGC_60 Homo Sapiens cDNA Clone IMAGE: 4807718 5' mRNA Sequence," Created April 24, 2001, (sequence) GenBank [online] Bethesda, MD, USA: National Center for Biotechnology Information [retrieved on October 5, 2001]. Retrieved from the Internet: URL: http://www.ncbi.nlm.nih.gov/ . GenBank Accession No. BG778739.				
	A8	STRAUSBERG, ROBERT, "602571324F1 NIH_MGC_77 Homo Sapiens cDNA Clone IMAGE: 4695796 5' mRNA Sequence," Created April 2, 2001, (sequence) GenBank [online] Bethesda, MD, USA: National Center for Biotechnology Information [retrieved on October 5, 2001]. Retrieved from the Internet: URL: http://www.ncbi.nlm.nih.gov/ . GenBank Accession No. BG542104.				
	A9	HEDGE, P., et al., "EST369130 MAGE Resequences, MAGD Homo Sapiens cDNA, mRNA Sequence," Created June 1, 2000, (sequence) GenBank [online] Bethesda, MD, USA: National Center for Biotechnology Information [retrieved on October 5, 2001]. Retrieved from the Internet: URL: http://www.ncbi.nlm.nih.gov/ . GenBank Accession No. AW957060.				
	A10	STRAUSBERG, ROBERT, "7d27a05.x1 NCI_CGAP_Pr28 Homo Sapiens cDNA Clone IMAGE: 3248432 3' mRNA Sequence," Created September 8, 2000, (sequence) GenBank [online] Bethesda, MD, USA: National Center for Biotechnology Information [retrieved on October 5, 2001]. Retrieved from the Internet: URL: http://www.ncbi.nlm.nih.gov/ . GenBank Accession No. BE672260.				
	A11	STRAUSBERG, ROBERT, "602303992F1 NIH_MGC_88 Homo Sapiens cDNA Clone IMAGE: 4395335 5' mRNA Sequence," Created January 22, 2001, (sequence) GenBank [online] Bethesda, MD, USA: National Center for Biotechnology Information [retrieved on October 5, 2001]. Retrieved from the Internet: URL: http://www.ncbi.nlm.nih.gov/ . GenBank Accession No. BF980807.				

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation design number. ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop DD, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Application Number	10/782,695
Sheet	2	of	3	Filing Date	February 19, 2004
				First Named Inventor	Maria A. Glucksmann, et al.
				Group Art Unit	1646
				Examiner Name	Jiang, Dong
				Attorney Docket Number	MPI04-002OMNIM

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and-or country where published.			
	A12	TOGAYACHI, A., et al., "Homo Sapiens Beta3GnT5 mRNA for Beta1, 3-N-Acetylglucosaminyltransferase 5, Complete Cds," June 22, 2001, (sequence) GenBank [online] Bethesda, MD, USA: National Center for Biotechnology Information [retrieved on October 5, 2001]. Retrieved from the Internet: URL: http://www.ncbi.nlm.nih.gov/ . GenBank Accession No. AB045278.			T ²
	A13	ZHOU, D., et al., "Homo Sapiens Beta 1,3 -N-Acetylglucosaminyltransferase Lc3 Synthase mRNA, Complete Cds," August 7, 2001, (sequence) GenBank [online] Bethesda, MD, USA: National Center for Biotechnology Information [retrieved on October 5, 2001]. Retrieved from the Internet: URL: http://www.ncbi.nlm.nih.gov/ . GenBank Accession No. AF368169.			
	A14	TOGAYACHI, A., et al., "Rattus Norvegicus Beta3GnT5 mRNA for Beta1, 3-N-Acetylglucosaminyltransferase 5, Partial Cds," June 22, 2001, (sequence) GenBank [online] Bethesda, MD, USA: National Center for Biotechnology Information [retrieved on October 5, 2001]. Retrieved from the Internet: URL: http://www.ncbi.nlm.nih.gov/ . GenBank Accession No. AB045279.			
	A15	BAKER, K.P., et al., "Sequence 511 from Patent WO0107611," February 22, 2001, (sequence) GenBank [online] Bethesda, MD, USA: National Center for Biotechnology Information [retrieved on October 5, 2001]. Retrieved from the Internet: URL: http://www.ncbi.nlm.nih.gov/ . GenBank Accession No. AX079767.			
	A16	BAKER, K.P., et al., "Sequence 507 from Patent WO0107611," February 22, 2001, (sequence) GenBank [online] Bethesda, MD, USA: National Center for Biotechnology Information [retrieved on October 5, 2001]. Retrieved from the Internet: URL: http://www.ncbi.nlm.nih.gov/ . GenBank Accession No. AX079763.			
	B1	BAKER, K.P., et al., "Sequence 474 from Patent WO0107611," February 22, 2001, (sequence) GenBank [online] Bethesda, MD, USA: National Center for Biotechnology Information [retrieved on October 5, 2001]. Retrieved from the Internet: URL: http://www.ncbi.nlm.nih.gov/ . GenBank Accession No. AX079730.			
	B2	HUDSON, T., "Human STS WI-13813, Sequence Tagged Site," May 31, 1996, (sequence) GenBank [online] Bethesda, MD, USA: National Center for Biotechnology Information [retrieved on October 5, 2001]. Retrieved from the Internet: URL: http://www.ncbi.nlm.nih.gov/ . GenBank Accession No. G23534.			
	B3	JACOBS, K., et al., "EST Clone IJ1220," October 15, 1998, <i>The Derwent GENESEQ Database</i> , Thomson Scientific, 3501 Market Street, Philadelphia, PA 19104, [retrieved on October 5, 2001], DGene Accession No. V88980.			
	B4	JACOBS, K., et al., "Human Secreted Expressed Sequence Tag SEQ ID No: 1663" April 20, 2000, <i>The Derwent GENESEQ Database</i> , Thomson Scientific, 3501 Market Street, Philadelphia, PA 19104, [retrieved on October 5, 2001], DGene Accession No. A45088.			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation design number. ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case.

Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop DD, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT					
(use as many sheets as necessary)					
Sheet	3	of	3	Attorney Docket Number	MPI04-002OMNIM

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include the name of the author (in CAPTIAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and-or country where published.		
	B5	MATSUBARA, K., et al., "Human Gene Signature HUMGS06027" June 1, 1995, <i>The Derwent GENESEQ Database</i> , Thomson Scientific, 3501 Market Street, Philadelphia, PA 19104, [retrieved on October 5, 2001], DGene Accession No. T24045.		
	B6	JACOBS, K., et al., "Human Secreted Expressed Sequence Tag SEQ ID No: 682" April 20, 2000, <i>The Derwent GENESEQ Database</i> , Thomson Scientific, 3501 Market Street, Philadelphia, PA 19104, [retrieved on October 5, 2001], DGene Accession No. A41942.		
	B7	BRETON, C., et al., "Structure/Function Studies of Glycosyltransferases," <i>Curr. Opin. Struc. Biol.</i> , Vol. 9, pp. 563-71 (1999).		
	B8	CROUT, D.H.G., et al., "Glycosidases and Glycosyl Transferases in Glycoside and Oligosaccharide Synthesis," <i>Curr. Chem. Biol.</i> , Vol. 2, pp. 98-111 (1998).		
	B9	DIAS NETO, E., et al., "Shotgun Sequencing of the Human Transcriptome with ORF Expressed Sequence Tags," <i>Proc. Natl. Acad. Sci. U.S.A.</i> , Vol. 97(7), pp. 3491-6 (March 28, 2000).		

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation design number. ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop DD, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

APPLICANT FACSIMILE OF FORM PTO-1449 REV 7-80	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY DOCKET NO MNI-188	SERIAL NO. 09/945,254
LIST OF PUBLICATIONS CITED BY APPLICANT (Use several sheets if necessary)		APPLICANT Rachel Meyers et al.	FILING DATE August 31, 2001
		GROUP	

U.S. PATENT DOCUMENTS

U.S. PATENT DOCUMENTS						
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
							YES NO

OTHERS (including Author, Title, Date, Pertinent Pages, Etc.)

Examiner

Date Considered

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Notice of References Cited

JUL 24 2006

Application/Control No.

09/945,254

Applicant(s)/Patent Under

Reexamination

MEYERS ET AL.

Examiner

Manjunath N. Rao, Ph.D.

Art Unit

1652

Page 1 of 1

U.S. PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification
	A	US-			
	B	US-			
	C	US-			
	D	US-			
	E	US-			
	F	US-			
	G	US-			
	H	US-			
	I	US-			
	J	US-			
	K	US-			
	L	US-			
	M	US-			

FOREIGN PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
	N	WO 01/44479 A1	12-2000	PCT	Conklin et al.	---
	O					
	P					
	Q					
	R					
	S					
	T					

NON-PATENT DOCUMENTS

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
	U	Conklin et al. GenSeq Accession No. AAE04752, 9-10-01.
	V	
	W	
	X	

*A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).)
Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.

*MMD
4/12/03*